KR102746352B1 - 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 - Google Patents

트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 Download PDF

Info

Publication number
KR102746352B1
KR102746352B1 KR1020247002643A KR20247002643A KR102746352B1 KR 102746352 B1 KR102746352 B1 KR 102746352B1 KR 1020247002643 A KR1020247002643 A KR 1020247002643A KR 20247002643 A KR20247002643 A KR 20247002643A KR 102746352 B1 KR102746352 B1 KR 102746352B1
Authority
KR
South Korea
Prior art keywords
pyridin
amine
isoxazolo
optionally substituted
substituted aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247002643A
Other languages
English (en)
Korean (ko)
Other versions
KR20240017411A (ko
Inventor
브라이언 데즈먼드 팔메
라이 밍 칭
스와나라타 아쿠라티야 가마지
Original Assignee
오클랜드 유니서비시즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오클랜드 유니서비시즈 리미티드 filed Critical 오클랜드 유니서비시즈 리미티드
Priority to KR1020247042036A priority Critical patent/KR20250007032A/ko
Publication of KR20240017411A publication Critical patent/KR20240017411A/ko
Application granted granted Critical
Publication of KR102746352B1 publication Critical patent/KR102746352B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247002643A 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 Active KR102746352B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247042036A KR20250007032A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ62868814 2014-08-13
NZ628688 2014-08-13
KR1020177006662A KR20170034439A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
PCT/IB2015/056129 WO2016024233A1 (en) 2014-08-13 2015-08-12 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006662A Division KR20170034439A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247042036A Division KR20250007032A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Publications (2)

Publication Number Publication Date
KR20240017411A KR20240017411A (ko) 2024-02-07
KR102746352B1 true KR102746352B1 (ko) 2024-12-24

Family

ID=55303920

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247002643A Active KR102746352B1 (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
KR1020177006662A Ceased KR20170034439A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
KR1020247042036A Pending KR20250007032A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177006662A Ceased KR20170034439A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
KR1020247042036A Pending KR20250007032A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Country Status (10)

Country Link
US (3) US10888567B2 (enExample)
EP (1) EP3180002B1 (enExample)
JP (2) JP7323985B2 (enExample)
KR (3) KR102746352B1 (enExample)
CN (3) CN106794176A (enExample)
AU (2) AU2015302908B2 (enExample)
CA (1) CA2957884A1 (enExample)
ES (1) ES2925471T3 (enExample)
WO (1) WO2016024233A1 (enExample)
ZA (1) ZA201700924B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102746352B1 (ko) 2014-08-13 2024-12-24 오클랜드 유니서비시즈 리미티드 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
AU2016312848A1 (en) * 2015-08-27 2018-03-29 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
RU2619120C1 (ru) * 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике
EP3269714A1 (en) 2016-07-13 2018-01-17 Netherlands Translational Research Center B.V. Inhibitors of tryptophan 2,3-dioxygenase
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
CN106905256A (zh) * 2017-03-06 2017-06-30 中国药科大学 苯并五元杂环类ido1抑制剂、其制备方法及应用
EP3697791A4 (en) 2017-10-19 2021-06-16 JS Innopharm (Shanghai) Ltd. HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
CN118740348A (zh) 2018-03-14 2024-10-01 华为技术有限公司 数据传输方法、装置及系统
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
JP6912016B1 (ja) * 2020-04-10 2021-07-28 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
EP4301358A2 (en) 2021-03-05 2024-01-10 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
JP2025507981A (ja) 2022-03-04 2025-03-21 アンティド セラピューティクス インターナショナル ソシエテ ア レスポンサビリテ リミティー トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の二重阻害剤と療法におけるそれらの使用
WO2025046519A1 (en) * 2023-08-31 2025-03-06 Antido Therapeutics International Sarl Combination for use in the treatment of glioma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520246A (ja) 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン
WO2013104561A1 (en) 2012-01-12 2013-07-18 Basf Se Herbicidal isoxazolo[5,4-b]pyridines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL123588B1 (en) 1979-12-20 1982-10-30 Akad Rolnicza Rotary dynamometer for measurement of useful work of machining
WO2001079193A2 (en) * 2000-04-14 2001-10-25 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
US20070197610A1 (en) 2004-03-16 2007-08-23 Janssen Pharmaceutica N.V. Benzisoxazoles
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
RS52711B (sr) * 2005-05-10 2013-08-30 Incyte Corporation Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
WO2010068452A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068453A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
JP2013519685A (ja) * 2010-02-11 2013-05-30 ヴァンダービルト ユニバーシティー ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法
US20100234491A1 (en) * 2010-05-27 2010-09-16 Morteza Khorrami Method and material for manufacturing fiber cement board
PL2595995T3 (pl) * 2010-07-22 2016-05-31 Basf Se Chwastobójcze izoksazolo[5,4-b]pirydyny
JP5672077B2 (ja) * 2011-03-04 2015-02-18 セイコーエプソン株式会社 発光素子、発光装置、表示装置および電子機器
PL220630B1 (pl) * 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
HUE039473T2 (hu) 2013-03-14 2019-01-28 Curadev Pharma Private Ltd Kinurenin útvonal inhibitorok
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
KR102746352B1 (ko) 2014-08-13 2024-12-24 오클랜드 유니서비시즈 리미티드 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
RU2619120C1 (ru) 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520246A (ja) 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン
WO2013104561A1 (en) 2012-01-12 2013-07-18 Basf Se Herbicidal isoxazolo[5,4-b]pyridines

Also Published As

Publication number Publication date
JP2021006579A (ja) 2021-01-21
EP3180002B1 (en) 2022-04-20
US12508268B2 (en) 2025-12-30
CA2957884A1 (en) 2016-02-18
CN117618423A (zh) 2024-03-01
US10888567B2 (en) 2021-01-12
ES2925471T3 (es) 2022-10-18
EP3180002A4 (en) 2018-07-04
CN106794176A (zh) 2017-05-31
CN117599049A (zh) 2024-02-27
AU2020203116B2 (en) 2021-10-21
JP2017527548A (ja) 2017-09-21
WO2016024233A1 (en) 2016-02-18
US20210145839A1 (en) 2021-05-20
AU2015302908B2 (en) 2020-02-13
AU2020203116A1 (en) 2020-05-28
ZA201700924B (en) 2022-11-30
KR20170034439A (ko) 2017-03-28
KR20250007032A (ko) 2025-01-13
US11826316B2 (en) 2023-11-28
KR20240017411A (ko) 2024-02-07
JP7323985B2 (ja) 2023-08-09
EP3180002A1 (en) 2017-06-21
US20170224701A1 (en) 2017-08-10
US20240285641A1 (en) 2024-08-29
AU2015302908A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
US12508268B2 (en) Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
JP6254169B2 (ja) ベンズアミドおよびヘテロベンズアミド化合物
AU2021212003B2 (en) INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY
JP5872027B2 (ja) ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
HU227972B1 (en) Phthalazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them
US10851054B2 (en) Derivatives of indole for the treatment of cancer, viral infections and lung diseases
WO2022213932A1 (zh) 吡咯并嘧啶酮类化合物及其应用
CN116283953B (zh) 含噻唑结构的吲哚啉类化合物及其制备方法和应用
HK1238549B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549A1 (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
WO2025038782A1 (en) Adenosine ligands for the treatment of neurological disorders or chronic heart failure
HK1258665B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240123

Application number text: 1020177006662

Filing date: 20170309

PG1501 Laying open of application
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240921

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241219

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241219

End annual number: 3

Start annual number: 1

PG1601 Publication of registration